APA (7th ed.) Citation

RM, F., H, B., FJ, B., TJ, S., C, P., S, C., . . . MC, L. (2019). A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis & rheumatology (Hoboken, N.J.), 71(7), 1056. https://doi.org/10.1002/art.40840

Chicago Style (17th ed.) Citation

RM, Fleischmann, et al. "A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis." Arthritis & Rheumatology (Hoboken, N.J.) 71, no. 7 (2019): 1056. https://doi.org/10.1002/art.40840.

MLA (9th ed.) Citation

RM, Fleischmann, et al. "A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis." Arthritis & Rheumatology (Hoboken, N.J.), vol. 71, no. 7, 2019, p. 1056, https://doi.org/10.1002/art.40840.